VAXCYTE, INC. Accrued Liabilities, Current
VAXCYTE, INC. (PCVX) had Accrued Liabilities, Current of $24.73 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Accrued Liabilities, Current $24.73M.
- 2026-03-31: Accrued Liabilities, Current $30.25M.
- 2025-12-31: Accrued Liabilities, Current $31.07M.
- 2025-09-30: Accrued Liabilities, Current $24.59M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $24.73M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $30.25M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $31.07M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $24.59M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $32.21M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $26.04M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $29.12M 10-K · filed 2026-02-24 |
| 2024-09-30 | $30.75M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $22.15M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $54.17M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $59.81M 10-K · filed 2025-02-25 |
| 2023-09-30 | $15.02M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $19.18M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $18.35M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $15.38M 10-K · filed 2024-02-27 |
| 2022-09-30 | $13.68M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $9.89M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $7.74M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $8.79M 10-K · filed 2023-02-27 |
| 2021-09-30 | $12.03M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $7.53M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $5.77M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $3.77M 10-K · filed 2022-02-28 |
| 2020-09-30 | $2.87M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $3.30M 10-Q · filed 2020-08-12 |
| 2019-12-31 | $1.30M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |